Norbert Müller
Elif Weidinger1- 1Department of Psychiatry and Psychotherapy, Ludwig Maximilian University, Munich, Germany
- 2Department of Laboratory Medicine, Ludwig Maximilian University, Munich, Germany
High levels of pro-inflammatory substances such as cytokines have been described in the blood and cerebrospinal fluid of schizophrenia patients. Animal models of schizophrenia show that under certain conditions an immune disturbance during early life, such as an infection-triggered immune activation, might trigger lifelong increased immune reactivity. A large epidemiological study clearly demonstrated that severe infections and autoimmune disorders are risk factors for schizophrenia. Genetic studies have shown a strong signal for schizophrenia on chromosome 6p22.1, in a region related to the human leucocyte antigen (HLA) system and other immune functions. Another line of evidence demonstrates that chronic (dis)stress is associated with immune activation. The vulnerability-stress-inflammation model of schizophrenia includes the contribution of stress on the basis of increased genetic vulnerability for the pathogenesis of schizophrenia, because stress may increase pro-inflammatory cytokines and even contribute to a lasting pro-inflammatory state. Immune alterations influence the dopaminergic, serotonergic, noradrenergic, and glutamatergic neurotransmission. The activated immune system in turn activates the enzyme indoleamine 2,3-dioxygenase (IDO) of the tryptophan/kynurenine metabolism which influences the serotonergic and glutamatergic neurotransmission via neuroactive metabolites such as kynurenic acid. The described loss of central nervous system volume and the activation of microglia, both of which have been clearly demonstrated in neuroimaging studies of schizophrenia patients, match the assumption of a (low level) inflammatory neurotoxic process. Further support for the inflammatory hypothesis comes from the therapeutic benefit of anti-inflammatory medication. Metaanalyses have shown an advantageous effect of cyclo-oxygenase-2 inhibitors in early stages of schizophrenia. Moreover, intrinsic anti-inflammatory, and immunomodulatory effects of antipsychotic drugs are known since a long time. Anti-inflammatory effects of antipsychotics, therapeutic effects of anti-inflammtory compounds, genetic, biochemical, and immunological findings point to a major role of inflammation in schizophrenia.
Introduction
We humans are constantly being assaulted by infectious agents, noxious chemicals, and physical traumata. Fortunately, we have evolved a complex process, the inflammatory response, to help fight and clear infection, remove damaging chemicals, and repair damaged tissue (O'Neill, 2008). The harmful effects of inflammation can be observed in many infectious and autoimmune diseases. The interactions between environmental factors and genetically encoded components of the inflammatory response determine whether the outcome will be health or disease.
As in other sites of the body, inflammation in the central nervous system (CNS) has a dual role, i.e., it may be neuroprotective or neurotoxic (Hohlfeld et al., 2007). While acute inflammation in the CNS (e.g., acute encephalitis) leads to life-threatening states within hours or days, chronic inflammation might be associated with impairment over months, years, or a lifetime.
As an example, multiple sclerosis (MS) is an inflammatory disease of the CNS that shows a relapsing-remitting course and, in a certain percentage of patients, also a chronic, progressive course. Parallels between MS and schizophrenia, which also often shows a chronic course, have repeatedly been highlighted as arguments for similar pathogenetic mechanisms in these disorders (Hanson and Gottesman, 2005).
The concept of “smoldering inflammation” implies that CNS inflammation drives the disease process in both acute and chronic stages (Kutzelnigg et al., 2005). While during acute inflammation the peripheral immune system interacts closely with the CNS, which is invaded by macrophages and B and T cells, in chronic processes the immune response in the CNS is thought to be increasingly secluded from the peripheral immune system (“compartmentalization” of the inflammatory process; Meinl et al., 2008; Kerschensteiner et al., 2009). Chronic MS, for example, is primarily characterized by disseminated activation of microglial cells.
There are numerous descriptions of an association between infection, chronic inflammation of the CNS, and schizophrenia (Anderson et al., 2013). For example, symptoms of schizophrenia have been described in the encephalitic form of MS (Felgenhauer, 1990), in viral CNS infection with herpes simplex virus type 1 (HSV-1; Chiveri et al., 2003), HSV-2 (Oommen et al., 1982), and measles (Hiroshi et al., 2003) and also in autoimmune processes such as poststreptococcal disorders (Mercadante et al., 2000; Bechter et al., 2007; Kerbeshian et al., 2007; Teixeira et al., 2007), lupus erythematodes, and scleroderma (van Dam, 1991; Müller et al., 1992, 1993; Nikolich-Zugich, 2008).
Inflammatory Mechanisms in the CNS
Inflammation in the CNS is mediated by pro-inflammatory cytokines, microglial cells (resident macrophages in the brain), astrocytes, and invading immune cells such as monocytes, macrophages, and T or B lymphocytes. Although a well-regulated inflammatory process is essential for tissue homeostasis and proper function, an excessive inflammatory response can be the source of additional injury to host cells. Uncontrolled inflammation may be the result of either infectious agents (e.g., bacteria, viruses) or a reaction to neuronal lesions from traumata, a genetic defect or environmental toxins.
Microglia as an Important Cellular basis of Inflammation in the CNS
Microglia comprise ~15% of the total CNS cells and are the primary component of the intrinsic immune system in the CNS, where they provide the first line of defense after injury or disease and are the principal component of neuroinflammation.
Microglia can be activated in different ways:
(1) A systemic inflammatory challenge triggers microglia activation, resulting in the release of proinflammatory cytokines in the CNS, which can mediate “sickness behavior” (Dantzer, 2001) and other mental states. Microglia play a role in the synthesis of these central cytokines (van Dam, 1991).
(2) Microglia are “sensitized” or “primed” (Perry, 2007) by different stimuli, including neurodegeneration (Cunningham et al., 2005), aging (Godbout and Johnson, 2009), and stress (Sparkman and Johnson, 2008). This process of sensitization or priming results in the elicitation of an exaggerated immune response to a weak stimulus. After priming, a second stimulus, e.g., low systemic inflammation or stress, may lead to microglia proliferation and increased production of proinflammatory cytokines by microglia (Frank et al., 2007). This exaggerated cytokine response may result in acute changes in behavior by exacerbating or re-exacerbating an inflammatory pathology in the CNS.
Kindling and Sensitization of the Immune Response: The Basis for the Stress-induced Inflammatory Response in Psychiatric Disorders
The immune response and the release of cytokines can become more sensitized to activating stimuli by a kindling process: the initial immune response, i.e., the release of cytokines and other mediators of immune activation, is initiated as a result of exposure to a certain stimulus; thereafter, either re-exposure to the same stimulus, e.g., stress or infection, is associated with an increased release of cytokines or a weaker stimulus is necessary for the same activation process. This “sensitization” or “kindling” may be due to the memory function of the acquired immune system (Furukawa et al., 1998; Sparkman and Johnson, 2008). Stress-associated release of IL-6 was shown to reactivate (prenatally) conditioned processes (Zhou et al., 1993). In healthy persons, a second stimulus (e.g., systemic inflammation, stress) led to immune activation, associated with cellular proliferation, and increased production and release of proinflammatory cytokines (Frank et al., 2007). This mechanism is a key mechanism for triggering an immune activation and inflammation, e.g., the stress-induced immune activation leading to psychopathological symptoms. A sensitization process in the immune system is in accordance with the view that after an infection during early childhood, re-infection or another stimulation of the immune system in later stages of life might be associated with a boosted release of sensitized cytokines, resulting in neurotransmitter disturbances.
Sensitization phenomena play a role in stress-related, cytokine-induced, neurotransmitter-mediated behavioral abnormalities, i.e., the cytokine response to a stimulus increases while the intensity of the stimulus decreases (Sparkman and Johnson, 2008). In animal experiments, however, cytokines promote greater neurotransmitter responses when the animals are re-exposed to the cytokine (Anisman and Merali, 2003), for example TNF-α (Hayley et al., 2002). In the CNS, the stress-induced activation and proliferation of microglia may mediate these cytokine effects (Nair and Bonneau, 2006).
The Vulnerability-Stress-Inflammation Model of Schizophrenia
The vulnerability-stress model of psychiatric disorders, first postulated for schizophrenia more than 30 years ago (Zubin and Spring, 1977), focuses on the role of physical and mental stress in triggering a psychotic episode. This model says that in especially vulnerable individuals (e.g., genetically vulnerable) stress represents an additional risk for the outbreak of the schizophrenic disease. An increased vulnerability of the offspring was shown—in addition to genetic vulnerability—if an inflammatory response was induced in the mother during the second trimester of pregnancy or in the offspring during later stages of CNS development in animal models (Giovanoli et al., 2013; Green et al., 2014). A recent study, the first large-scale epidemiological study in psychiatry, showed, however, that severe infections and autoimmune disorders increase additively the risk of schizophrenia and schizophrenia spectrum disorders also in adults (Benros et al., 2011).
The underlying mechanisms of the co-occurrence of stress and inflammation were studied in animal experiments and stress was repeatedly shown to be associated with an increase in pro-inflammatory cytokines (Sparkman and Johnson, 2008).
The specific influence of the inflammatory mechanisms on neurotransmitter systems in schizophrenia will be discussed below. Moreover, the modulation of glutamatergic neurotransmission will be highlighted; glutamate is the most abundant neurotransmitter in the CNS and differ-entially involved via cytokine-directed tryptophan/kynurenine metabolism in schizophrenia, presumably but not exclusively mediated by NMDA receptors. Besides others, genetic factors of the kynurenine metabolites play a role (Claes et al., 2011).
The Immune Dysbalance in Schizophrenia is Associated with Chronic Inflammation
Degradation products of inflammatory substances have been described in schizophrenic brain tissue (Körschenhausen et al., 1996) and in the CSF of about 50% of schizophrenia patients (Wildenauer et al., 1991).
Regarding the cytokine pattern in schizophrenia, a blunted type 1 [e.g., Interferon(IFN)-gamma, Interleukin(IL)-2, soluble IL-2 receptors] and (compensatory) increased type 2 cytokine pattern (e.g., IL-6, IL-10) have been repeatedly observed in unmedicated schizophrenia patients (Müller and Schwarz, 2006). These findings point to an imbalance of the type 1 and type 2 immune responses in schizophrenia. Overviews on the imbalance in schizophrenia of the type 1 and type 2 and the pro- and anti-inflammatory immune systems as well as innate immunity, including the monocyte/macrophage system (Sperner-Unterweger et al., 1992), have recently been published and indicate that an inflammatory process plays an important role in the pathophysiology of at least a subgroup of schizophrenia patients (Potvin et al., 2008; Müller and Schwarz, 2010; Miller et al., 2011). Accordingly, first pilot experiences with the type 1-stimulating substance interferon-gamma (IFN-γ) as a therapeutic approach in schizophrenia are encouraging (Grüber et al., 2014).
The Impact of Inflammation on Neurotransmitters in Schizophrenia
Over the last five decades, research on the neurobiology of schizophrenia has focused overwhelmingly on disturbances of dopaminergic neurotransmission (Carlsson, 1988). There is no doubt that a dysfunction of the dopamine system is involved in the pathogenesis of schizophrenia, although the mechanism is not clear and antidopaminergic antipsychotic drugs still show unsatisfactory therapeutic effects.
IL-1β, which can induce the conversion of rat mesencephalic progenitor cells into a dopaminergic phenotype (Kabiersch et al., 1998; Ling et al., 1998; Potter et al., 1999), and IL-6, which is highly effective in decreasing the survival of fetal brain serotonergic neurons (Jarskog et al., 1997), seem to have an important influence on the development of the neurotransmitter systems involved in schizophrenia, although the specificity of these cytokines is a matter of discussion. Maternal immune stimulation during pregnancy was shown to increase the number of mesencephalic dopaminergic neurons in the fetal brain (Winter et al., 2009); the increase was probably associated with a dopaminergic excess in the midbrain (Winter et al., 2009). Persistent pathogens might be key factors that drive imbalances of the immune reaction (Nikolich-Zugich, 2008). Nevertheless, many questions about how immunity and immune pathology are involved in virus infections remain unanswered (Rouse and Sehrawat, 2010).
Much evidence seems to indicate that a lack of glutamatergic neurotransmission, mediated via NMDA antagonism, is a key mechanism in the pathophysiology of schizophrenia (Müller and Schwarz, 2007; Genius et al., 2013; Goff, 2015; Howes et al., 2015). The only NMDA receptor antagonist known to occur naturally in the human CNS is kynurenic acid (Stone, 1993), one of at least three neuroactive intermediate products of the kynurenine pathway. A predominant type 2 immune response inhibits the enzyme indoleamine 2,3-dioxygenase (IDO), resulting in an increased production of kynurenic acid in schizophrenia and in NMDA receptor antagonism (Müller and Schwarz, 2007; Müller et al., 2011). The recent finding of NMDA receptor antibodies in about 10% of acute (unmedicated) schizophrenia patients is especially interesting in this regard (Vincent and Bien, 2008; Steiner et al., 2013).
Discrepancies in the findings regarding kynurenic acid in schizophrenia, however, have to be discussed (Kegel et al., 2014). Elevated kynurenic acid has mainly been described in the CSF (Erhardt et al., 2001; Linderholm et al., 2012), in the brains of schizophrenia patients (Schwarcz et al., 2001; Sathyasaikumar et al., 2011) and in animal models of schizophrenia (Olsson et al., 2009). However, no increased kynurenic acid levels were observed in the peripheral blood of first-episode schizophrenia patients (Condray et al., 2011) and other groups of schizophrenia patients (Myint et al., 2011). In a toxoplasma animal model the relationship between IDO, infection, kynurenine metabolites, and schizophrenia is exemplified (Notarangelo et al., 2014). Antipsychotic medication, however, influences kynurenine metabolites and has to be regarded as an interfering variable (Ceresoli-Borroni et al., 2006; Condray et al., 2011; Myint et al., 2011).
Infection as a Risk Factor Schizophrenia
Prenatal immune activation—infection triggered or not—is an important risk factor for schizophrenia (Meyer et al., 2011). Animal models of schizophrenia show that stimulation of the maternal immune system during pregnancy by viral or bacterial agents leads to typical (schizophrenia-like) symptoms, i.e., the disturbed prepulse inhibition in the offspring (Meyer and Feldon, 2009; Meyer et al., 2011).
Evidence for pre- or perinatal exposure to infections as a risk factor for schizophrenia has not only been obtained from animal models (Westergaard et al., 1999; Buka et al., 2001). Also in humans studies of infections as risk factors for schizophrenia have been performed on several viral disorders (Pearce, 2001; Brown et al., 2004a; Buka et al., 2008). An increased risk for schizophrenia in the offspring was observed after respiratory infections (Brown et al., 2000; Sørensen et al., 2009), genital infections, and reproductive tract infections (Babulas et al., 2006; Sørensen et al., 2009). Specifically, women during pregnancy infected with Toxoplasma gondii were intensely studied as risk factor for schizophrenia (Brown et al., 2005).
Infections before birth increase the risk for later schizophrenia (Gattaz et al., 2004; Boksa, 2008; Brown, 2008; Dalman et al., 2008), as do infections—in particular CNS infections—during later stages of brain development. Antibody titers against viruses have been examined in the sera of schizophrenia patients for many years (Yolken and Torrey, 1995). The results, however, have been inconsistent, e.g., because interfering factors were not controlled for. Antibody levels are associated with the medication state, a finding which partly explains the earlier controversial results (Leweke et al., 2004). In one of our own studies, higher titers of different pathogens were found in schizophrenia patients than in controls, a phenomenon that we called “infectious index” (Krause et al., 2010).
In humans, increased maternal levels of the proinflammatory cytokine interleukin-8 (IL-8) during pregnancy were shown to be associated with an increased risk for schizophrenia in the offspring, whatever the reason for the increase in IL-8 (Brown et al., 2004b). Moreover, increased maternal IL-8 levels in pregnancy were also significantly related to decreased brain volume, i.e., lower volumes of the right posterior cingulum and left entorhinal cortex and higher volumes of the ventricles in the schizophrenic offspring (Ellman et al., 2010).
A recent study, the first large-scale epidemiological study in psychiatry, showed, however, that severe infections and autoimmune disorders increase additively the risk of schizophrenia and schizophrenia spectrum disorders (Benros et al., 2011). This is an important finding, since mostly maternal infections during pregnancy had been studied before (in animal models). Infections after birth or during childhood and adolescence in later schizophrenic diagnosed patients—i.e., lifetime infections of the schizophrenia patients—have only rarely been studied (Benros et al., 2011, 2012). The sensitivity of the study in recording infections was not high, because only infections leading to hospital admissions were recorded. Normally, only extraordinary severe infections lead to a hospital contact. Therefore, despite the large scale of the study, it may have clearly identified only the “tip of an iceberg” of risk factors (Benros et al., 2012).
CNS Volume Loss in Imaging Studies—a Consequence of an Inflammatory Process?
Gross inflammatory changes have not been found in neuroimaging or neuropathological studies of schizophrenia. However, there is no doubt that a decreased CNS volume can be observed as early as the first episode and a progressive loss in CNS volume occurs during the further course of the disease (Chakos et al., 2005; Job et al., 2006; Steen et al., 2006; Gogtay et al., 2008). Moreover, a relationship was described between volume loss and an increased genetic risk for a higher production of the immune marker IL-1β (Meisenzahl et al., 2001); the relationship between maternal IL-8 levels and CNS volume was mentioned above (Ellman et al., 2010).
The ligand PK 11195 is used in positron emission tomography (PET) to estimate microglial activation (Versijpt et al., 2003). In schizophrenia, an increased expression of PK 11195 was shown to be a marker of an inflammatory process in the CNS (van Berckel et al., 2008; Doorduin et al., 2009). Moreover, positive correlations were also observed between expression of the microglial activation marker DAA1106 and both schizophrenia positive symptoms and duration of the disease (Takano et al., 2010).
Cyclooxygenase-2 (COX-2) Inhibition as an Anti-Inflammatory Therapeutic Approach in Schizophrenia
Modern anti-inflammatory agents have been explored in schizophrenia. The cyclooxygenase-2 (COX-2) inhibitor celecoxib was studied in a prospective, randomized, double-blind study of acute exacerbations of schizophrenia. The patients receiving celecoxib add-on to risperidone showed a statistically significantly better outcome than the patients receiving risperidone alone; the clinical effects of COX-2 inhibition in schizophrenia were especially pronounced in cognition (Müller et al., 2005). The efficacy of therapy with a COX-2 inhibitor seems most pronounced in the first years of the schizophrenic disease process (Müller, 2010; Müller et al., 2010). A recent study also demonstrated a beneficial effect of acetylsalicylic acid in schizophrenic spectrum disorders (Laan et al., 2010). A meta-analysis of the clinical effects of non-steroidal anti-inflammatory drugs in schizophrenia revealed significant effects on schizophrenic total, positive and negative symptoms (Sommer et al., 2012), while another meta-analysis found a significant benefit only in schizophrenia patients with a short duration of disease or in first manifestation schizophrenia (Nitta et al., 2013).
Further Immune-related Substances in the Therapy of Schizophrenia
Because of the role of microglia activation in inflammation, minocycline, an antibiotic and inhibitor of microglia activation, is an interesting substance for the treatment of schizophrenia. The improvement of cognition by minocycline has been described in animal models of schizophrenia (Mizoguchi et al., 2008) and in two double-blind, placebo-controlled add-on therapy trials in schizophrenia patients (Levkovitz et al., 2010; Chaudhry et al., 2012). In clinical studies, positive effects on schizophrenic negative symptoms were noted as well (Chaudhry et al., 2012). Case reports documented positive effects of minocycline on the whole symptom spectrum in schizophrenia (Ahuja and Carroll, 2007).
Acetylcysteine (ACC) and other substances, including omega-3 fatty acids, that have anti-inflammatory and other effects also provide some benefit to schizophrenia patients (overview: Sommer et al., 2014)
First pilot experiences with cytokine interferon gamma (IFN-γ), which stimulates the monocytic type 1 immune response, as a therapeutic approach in schizophrenia are encouraging (Grüber et al., 2014), although side effects, including unwanted immune effects, have to be carefully monitored and the results are only preliminary. On the other hand, such a hypothesis-driven therapeutic approach opens interesting perspectives for the development of therapeutic substances based on etiopathology.
Methodological Aspects of the Response to Immune-based Therapy in Schizophrenia
The knowledge that schizophrenia is a syndrome and that different pathological mechanisms may play a role in the disorder seems to indicate that immune pathology is restricted to a subgroup of patients. Although several biological markers, including immune markers, are discussed to reflect subgroups of schizophrenia, so far no marker is established for an immune-related schizophrenia. Accordingly, an immune-based therapeutic approach might be effective only in a subgroup of patients or, put another way, an immune-based therapy can be expected to show only a small therapeutic effect in an unselected group of schizophrenia patients. Another relevant point is that all clinical studies with immune-based treatment are add-on studies to an established standard therapy with antipsychotics. For ethical reasons this design has to be used until the add-on substance has a proven effect in schizophrenia. In order to show superiority over an effective antipsychotic in monotherapy, however, the add-on substance has to have a huge additional effect before it reaches statistical significance over placebo and the antipsychotic. In the light of high and increasing placebo response rates in schizophrenia studies (Rutherford et al., 2014), anti-inflammatory substances need high effect sizes to show statistical superiority in double-blind, randomized, placebo-controlled studies. Moreover, schizophrenia patients participating in clinical studies, and especially in studies with a new, unproven therapeutic approach, often show an unfavorable, sometimes therapy-resistant course of the disorder, i.e., several of the studies may include a “negative” selection of severely ill patients.
The above mentioned methodological aspects may explain the difficulties in showing a convincing effect of anti-inflammatory drugs in schizophrenia.
Conclusion
The possible influence on the pathogenesis of schizophrenia of an immunological process resulting in inflammation has long been neglected. Increasing evidence for a role of proinflammatory cytokines in schizophrenia, the strong influence of pro- and anti-inflammatory cytokines on tryptophan/kynurenine metabolism, the related influence of cytokines on glutamatergic neurotransmission, the results of imaging studies, genetic findings and, last but not least, the therapeutic effect of anti-inflammatory drugs all support the view that the recent increased focus of schizophrenia research on psychoneuroimmunology and inflammation is justified. On the other hand, one has to consider that immunological research is susceptible to artifacts, i.e., interfering variables such as medication, smoking, stress, sleep, and others play an important role and cannot always be controlled. This is exemplified by stress, which, according to the “vulnerability-stress model,” is not only a condition sine qua non in schizophrenia but is also a confounding factor in research of the immune system and inflammatory processes. The situation is similar for neuro-imaging studies: volume loss might be the result of different pathological processes other than inflammatory ones. Nevertheless, the results of these studies are encouraging and further studies should focus on the relationship between inflammatory markers in the blood and CSF and volume loss in the CNS. Moreover, the influence of different disease stages in schizophrenia might also have been neglected. The syndrome of schizophrenia is discussed to have different underlying pathological processes. Inflammation, however, also includes different stages and processes ranging from acute to chronic inflammation, including an autoimmune process.
These considerations show that although a lot of further research is necessary to clarify the role of the immune system in schizophrenia, recent findings encourage continued emphasis on this fascinating field.
Funding
This work was supported by the Foundation “Immunität und Seele”.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
Parts of this manuscript have been published before: Müller and Bechter (2013) and Müller (2014). The authors thank Jacquie Klesing, Board-certified Editor in the Life Sciences (ELS), for editing assistance with the manuscript.
References
Ahuja, N., and Carroll, B. T. (2007). Possible anti-catatonic effects of minocycline in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 968–969. doi: 10.1016/j.pnpbp.2007.01.018
Anderson, G., Berk, M., Dodd, S., Bechter, K., Altamura, A. C., Dell'osso, B., et al. (2013). Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 42, 1–4. doi: 10.1016/j.pnpbp.2012.10.008
Anisman, H., and Merali, Z. (2003). Cytokines, stress and depressive illness: brain-immune interactions. Ann. Med. 35, 2–11. doi: 10.1080/07853890310004075
Babulas, V., Factor-Litvak, P., Goetz, R., Schaefer, C. A., and Brown, A. S. (2006). Prenatal exposure to maternal genital and reproductive infections and adult schizophrenia. Am. J. Psychiatry 163, 927–929. doi: 10.1176/ajp.2006.163.5.927
Bechter, K., Bindl, A., Horn, M., and Schreiner, V. (2007). [Therapy-resistant depression with fatigue. A case of presumed streptococcal-associated autoimmune disorder]. Nervenarzt. 78, 338, 340–341. doi: 10.1007/s00115-006-2178-8
Benros, M. E., Mortensen, P. B., and Eaton, W. W. (2012). Autoimmune diseases and infections as risk factors for schizophrenia. Ann. N. Y. Acad. Sci. 1262, 56–66. doi: 10.1111/j.1749-6632.2012.06638.x
Benros, M. E., Nielsen, P. R., Nordentoft, M., Eaton, W. W., Dalton, S. O., and Mortensen, P. B. (2011). Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am. J. Psychiatry 168, 1303–1310. doi: 10.1176/appi.ajp.2011.11030516
Boksa, P. (2008). Maternal infection during pregnancy and schizophrenia. J. Psychiatry Neurosci. 33, 183–185.
Brown, A. S. (2008). The risk for schizophrenia from childhood and adult infections. Am. J. Psychiatry 165, 7–10. doi: 10.1176/appi.ajp.2007.07101637
Brown, A. S., Begg, M. D., Gravenstein, S., Schaefer, C. A., Wyatt, R. J., Bresnahan, M., et al. (2004a). Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch. Gen. Psychiatry 61, 774–780. doi: 10.1001/archpsyc.61.8.774
Brown, A. S., Cohen, P., Greenwald, S., and Susser, E. (2000). Nonaffective psychosis after prenatal exposure to rubella. Am. J. Psychiatry 157, 438–443. doi: 10.1176/appi.ajp.157.3.438
Brown, A. S., Hooton, J., Schaefer, C. A., Zhang, H., Petkova, E., Babulas, V., et al. (2004b). Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am. J. Psychiatry 161, 889–895. doi: 10.1176/appi.ajp.161.5.889
Brown, A. S., Schaefer, C. A., Quesenberry, C. P. Jr., Liu, L., Babulas, V. P., and Susser, E. S. (2005). Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am. J. Psychiatry 162, 767–773. doi: 10.1176/appi.ajp.162.4.767
Buka, S. L., Cannon, T. D., Torrey, E. F., and Yolken, R. H. (2008). Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biol. Psychiatry 63, 809–815. doi: 10.1016/j.biopsych.2007.09.022
Buka, S. L., Tsuang, M. T., Torrey, E. F., Klebanoff, M. A., Bernstein, D., and Yolken, R. H. (2001). Maternal infections and subsequent psychosis among offspring. Arch. Gen. Psychiatry 58, 1032–1037. doi: 10.1001/archpsyc.58.11.1032
Carlsson, A. (1988). The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1, 179–186. doi: 10.1016/0893-133X(88)90012-7
Ceresoli-Borroni, G., Rassoulpour, A., Wu, H. Q., Guidetti, P., and Schwarcz, R. (2006). Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J. Neural Transm. 113, 1355–1365. doi: 10.1007/s00702-005-0432-z
Chakos, M. H., Schobel, S. A., Gu, H., Gerig, G., Bradford, D., Charles, C., et al. (2005). Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br. J. Psychiatry 186, 26–31. doi: 10.1192/bjp.186.1.26
Chaudhry, I. B., Hallak, J., Husain, N., Minhas, F., Stirling, J., Richardson, P., et al. (2012). Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol. 26, 1185–1193. doi: 10.1177/0269881112444941
Chiveri, L., Sciacco, M., and Prelle, A. (2003). Schizophreniform disorder with cerebrospinal fluid PCR positivity for herpes simplex virus type 1. Eur. Neurol. 50, 182–183. doi: 10.1159/000073062
Claes, S., Myint, A. M., Domschke, K., Del-Favero, J., Entrich, K., Engelborghs, S., et al. (2011). The kynurenine pathway in major depression: haplotype analysis of three related functional candidate genes. Psychiatry Res. 188, 355–360. doi: 10.1016/j.psychres.2011.03.012
Condray, R., Dougherty, G. G. Jr., Keshavan, M. S., Reddy, R. D., Haas, G. L., Montrose, D. M., et al. (2011). 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int. J. Neuropsychopharmacol. 14, 756–767. doi: 10.1017/S1461145710001689
Cunningham, C., Wilcockson, D. C., Campion, S., Lunnon, K., and Perry, V. H. (2005). Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci. 25, 9275–9284. doi: 10.1523/JNEUROSCI.2614-05.2005
Dalman, C., Allebeck, P., Gunnell, D., Harrison, G., Kristensson, K., Lewis, G., et al. (2008). Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. Am. J. Psychiatry. 165, 59–65. doi: 10.1176/appi.ajp.2007.07050740
Dantzer, R. (2001). Cytokine-induced sickness behavior: where do we stand? Brain Behav. Immun. 15, 7–24. doi: 10.1006/brbi.2000.0613
Doorduin, J., de Vries, E. F., Willemsen, A. T., de Groot, J. C., Dierckx, R. A., and Klein, H. C. (2009). Neuroinflammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med. 50, 1801–1807. doi: 10.2967/jnumed.109.066647
Ellman, L. M., Deicken, R. F., Vinogradov, S., Kremen, W. S., Poole, J. H., Kern, D. M., et al. (2010). Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr. Res. 121, 46–54. doi: 10.1016/j.schres.2010.05.014
Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindström, L. H., and Engberg, G. (2001). Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 313, 96–98. doi: 10.1016/S0304-3940(01)02242-X
Felgenhauer, K. (1990). Psychiatric disorders in the encephalitic form of multiple sclerosis. J. Neurol. 237, 11–18. doi: 10.1007/BF00319661
Frank, M. G., Baratta, M. V., Sprunger, D. B., Watkins, L. R., and Maier, S. F. (2007). Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses. Brain Behav. Immun. 21, 47–59. doi: 10.1016/j.bbi.2006.03.005
Furukawa, H., del Rev, A., Monge-Arditi, G., and Besedovsky, H. O. (1998). Interleukin-1, but not stress, stimulates glucocorticoid output during early postnatal life in mice. Ann. N. Y. Acad. Sci. 840, 117–122. doi: 10.1111/j.1749-6632.1998.tb09555.x
Gattaz, W. F., Abrahão, A. L., and Foccacia, R. (2004). Childhood meningitis, brain maturation and the risk of psychosis. Eur. Arch. Psychiatry Clin. Neurosci. 254, 23–26. doi: 10.1007/s00406-004-0431-3
Genius, J., Geiger, J., Dölzer, A. L., Benninghoff, J., Giegling, I., Hartmann, A. M., et al. (2013). Glutamatergic dysbalance and oxidative stress in in vivo and in vitro models of psychosis based on chronic NMDA receptor antagonism. PLoS ONE 8:e59395. doi: 10.1371/journal.pone.0059395
Giovanoli, S., Engler, H., Engler, A., Richetto, J., Voget, M., Willi, R., et al. (2013). Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science 339, 1095–1099. doi: 10.1126/science.1228261
Godbout, J. P., and Johnson, R. W. (2009). Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. Immunol. Allergy Clin. North Am. 29, 321–337. doi: 10.1016/j.iac.2009.02.007
Goff, D. C. (2015). Drug development in schizophrenia: are glutamatergic targets still worth aiming at? Curr. Opin. Psychiatry 28, 207–215. doi: 10.1097/YCO.0000000000000152
Gogtay, N., Lu, A., Leow, A. D., Klunder, A. D., Lee, A. D., Chavez, A., et al. (2008). Three-dimensional brain growth abnormalities in childhood-onset schizophrenia visualized by using tensor-based morphometry. Proc. Natl. Acad. Sci. U.S.A. 105, 15979–15984. doi: 10.1073/pnas.0806485105
Green, M. J., Girshkin, L., Teroganova, N., and Quidé, Y. (2014). Stress, schizophrenia and bipolar disorder. Curr. Top. Behav. Neurosci. 18:217–235. doi: 10.1007/7854_2014_290
Grüber, L., Bunse, T., Weidinger, E., Reichard, H., and Müller, N. (2014). Adjunctive recombinant human interferon gamma-1b for treatment-resistant schizophrenia in 2 patients. J. Clin. Psychiatry 75, 1266–1267. doi: 10.4088/jcp.14l09005
Hanson, D. R., and Gottesman, I. I. (2005). Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med. Genet. 6:7. doi: 10.1186/1471-2350-6-7
Hayley, S., Wall, P., and Anisman, H. (2002). Sensitization to the neuroendocrine, central monoamine and behavioural effects of murine tumor necrosis factor-alpha: peripheral and central mechanisms. Eur. J. Neurosci. 15, 1061–1076. doi: 10.1046/j.1460-9568.2002.01936.x
Hiroshi, H., Seiji, K., Toshihiro, K., and Nobuo, K. (2003). [An adult case suspected of recurrent measles encephalitis with psychiatric symptoms]. Seishin Shinkeigaku Zasshi. 105, 1239–1246.
Hohlfeld, R., Kerschensteiner, M., and Meinl, E. (2007). Dual role of inflammation in CNS disease. Neurology 68, S58–S63. doi: 10.1212/01.wnl.0000275234.43506.9b
Howes, O., McCutcheon, R., and Stone, J. (2015). Glutamate and dopamine in schizophrenia: an update for the 21st century. J. Psychopharmacol. 29, 97–115. doi: 10.1177/0269881114563634
Jarskog, L. F., Xiao, H., Wilkie, M. B., Lauder, J. M., and Gilmore, J. H. (1997). Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int. J. Dev. Neurosci. 15, 711–716. doi: 10.1016/S0736-5748(97)00029-4
Job, D. E., Whalley, H. C., McIntosh, A. M., Owens, D. G., Johnstone, E. C., and Lawrie, S. M. (2006). Grey matter changes can improve the prediction of schizophrenia in subjects at high risk. BMC Med. 4:29. doi: 10.1186/1741-7015-4-29
Kabiersch, A., Furukawa, H., del Rey, A., and Besedovsky, H. O. (1998). Administration of interleukin-1 at birth affects dopaminergic neurons in adult mice. Ann. N. Y. Acad. Sci. 840, 123–127. doi: 10.1111/j.1749-6632.1998.tb09556.x
Kegel, M. E., Bhat, M., Skogh, E., Samuelsson, M., Lundberg, K., Dahl, M. L., et al. (2014). Imbalanced kynurenine pathway in schizophrenia. Int. J. Tryptophan. Res. 7, 15–22. doi: 10.4137/IJTR.S16800
Kerbeshian, J., Burd, L., and Tait, A. (2007). Chain reaction or time bomb: a neuropsychiatric-developmental/neurodevelopmental formulation of tourettisms, pervasive developmental disorder, and schizophreniform symptomatology associated with PANDAS. World J. Biol. Psychiatry 8, 201–207. doi: 10.1080/15622970601182652
Kerschensteiner, M., Meinl, E., and Hohlfeld, R. (2009). Neuro-immune crosstalk in CNS diseases. Neuroscience 158, 1122–1132. doi: 10.1016/j.neuroscience.2008.09.009
Körschenhausen, D. A., Hampel, H. J., Ackenheil, M., Penning, R., and Müller, N. (1996). Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr. Res. 19, 103–109. doi: 10.1016/0920-9964(95)00073-9
Krause, D., Matz, J., Weidinger, E., Wagner, J., Wildenauer, A., Obermeier, M., et al. (2010). The association of infectious agents and schizophrenia. World J. Biol. Psychiatry 11, 739–743. doi: 10.3109/15622971003653246
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., et al. (2005). Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 2705–2712. doi: 10.1093/brain/awh641
Laan, W., Grobbee, D. E., Selten, J. P., Heijnen, C. J., Kahn, R. S., and Burger, H. (2010). Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 71, 520–527. doi: 10.4088/JCP.09m05117yel
Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., et al. (2010). A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 71, 138–149. doi: 10.4088/JCP.08m04666yel
Leweke, F. M., Gerth, C. W., Koethe, D., Klosterkötter, J., Ruslanova, I., Krivogorsky, B., et al. (2004). Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 254, 4–8. doi: 10.1007/s00406-004-0481-6
Linderholm, K. R., Skogh, E., Olsson, S. K., Dahl, M. L., Holtze, M., Engberg, G., et al. (2012). Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr. Bull. 38, 426–432. doi: 10.1093/schbul/sbq086
Ling, Z. D., Potter, E. D., Lipton, J. W., and Carvey, P. M. (1998). Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines. Exp. Neurol. 149, 411–423. doi: 10.1006/exnr.1998.6715
Meinl, E., Krumbholz, M., Derfuss, T., Junker, A., and Hohlfeld, R. (2008). Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. J. Neurol Sci. 274, 42–44. doi: 10.1016/j.jns.2008.06.032
Meisenzahl, E. M., Rujescu, D., Kirner, A., Giegling, I., Kathmann, N., Leinsinger, G., et al. (2001). Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia. Am. J. Psychiatry 158, 1316–1319. doi: 10.1176/appi.ajp.158.8.1316
Mercadante, M. T., Busatto, G. F., Lombroso, P. J., Prado, L., Rosário-Campos, M. C., do Valle, R., et al. (2000). The psychiatric symptoms of rheumatic fever. Am. J. Psychiatry 157, 2036–2038. doi: 10.1176/appi.ajp.157.12.2036
Meyer, U., and Feldon, J. (2009). Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology (Berl). 206, 587–602. doi: 10.1007/s00213-009-1504-9
Meyer, U., Schwarz, M. J., and Müller, N. (2011). Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol. Ther. 132, 96–110. doi: 10.1016/j.pharmthera.2011.06.003
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., and Kirkpatrick, B. (2011). Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70, 663–671. doi: 10.1016/j.biopsych.2011.04.013
Mizoguchi, H., Takuma, K., Fukakusa, A., Ito, Y., Nakatani, A., Ibi, D., et al. (2008). Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology (Berl). 196, 233–241. doi: 10.1007/s00213-007-0955-0
Müller, N. (2010). COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr. Opin. Investig. Drugs 11, 31–42.
Müller, N. (2014). Immunology of schizophrenia. Neuroimmunomodulation 21, 109–116. doi: 10.1159/000356538
Müller, N., and Bechter, K. (2013). The mild encephalitis concept for psychiatric disorders revisited in the light of current psychoneuroimmunological findings. Neurol. Psychiatry Brain Res. 19, 87–101. doi: 10.1016/j.npbr.2013.04.004
Müller, N., Gizycki-Nienhaus, B., Botschev, C., and Meurer, M. (1993). Cerebral involvement of scleroderma presenting as schizophrenia-like psychosis. Schizophr. Res. 10, 179–181. doi: 10.1016/0920-9964(93)90054-M
Müller, N., Gizycki-Nienhaus, B., Günther, W., and Meurer, M. (1992). Depression as a cerebral manifestation of scleroderma: immunological findings in serum and cerebrospinal fluid. Biol. Psychiatry 31, 1151–1156. doi: 10.1016/0006-3223(92)90160-2
Müller, N., Krause, D., Dehning, S., Musil, R., Schennach-Wolff, R., Obermeier, M., et al. (2010). Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 121, 119–124. doi: 10.1016/j.schres.2010.04.015
Müller, N., Myint, A. M., and Schwarz, M. J. (2011). Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr. Pharm. Des. 17, 130–136. doi: 10.2174/138161211795049552
Müller, N., Riedel, M., Schwarz, M. J., and Engel, R. R. (2005). Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 255, 149–151. doi: 10.1007/s00406-004-0548-4
Müller, N., and Schwarz, M. J. (2006). Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders. Expert Rev. Neurother. 6, 1017–1038. doi: 10.1586/14737175.6.7.1017
Müller, N., and Schwarz, M. J. (2007). The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J. Neural. Transm. (Suppl. 72) 269–280. doi: 10.1007/978-3-211-73574-9_33
Müller, N., and Schwarz, M. J. (2010). Immune system and schizophrenia. Curr. Immunol. Rev. 6, 213–220. doi: 10.2174/157339510791823673
Myint, A. M., Schwarz, M. J., Verkerk, R., Mueller, H. H., Zach, J., Scharpé, S., et al. (2011). Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav. Immun. 25, 1576–1581. doi: 10.1016/j.bbi.2011.05.005
Nair, A., and Bonneau, R. H. (2006). Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J. Neuroimmunol. 171, 72–85. doi: 10.1016/j.jneuroim.2005.09.012
Nikolich-Zugich, J. (2008). Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. Nat. Rev. Immunol. 8, 512–522. doi: 10.1038/nri2318
Nitta, M., Kishimoto, T., Müller, N., Weiser, M., Davidson, M., Kane, J. M., et al. (2013). Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr. Bull. doi: 10.1093/schbul/sbt070
Notarangelo, F. M., Wilson, E. H., Horning, K. J., Thomas, M. A., Harris, T. H., Fang, Q., et al. (2014). Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia. Schizophr. Res. 152, 261–267. doi: 10.1016/j.schres.2013.11.011
Olsson, S. K., Andersson, A. S., Linderholm, K. R., Holtze, M., Nilsson-Todd, L. K., Schwieler, L., et al. (2009). Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. Int. J. Neuropsychopharmacol. 12, 501–512. doi: 10.1017/S1461145708009383
O'Neill, L. A. (2008). How frustration leads to inflammation. Science 320, 619–620. doi: 10.1126/science.1158398
Oommen, K. J., Johnson, P. C., and Ray, C. G. (1982). Herpes simplex type 2 virus encephalitis presenting as psychosis. Am. J. Med. 73, 445–448. doi: 10.1016/0002-9343(82)90751-3
Pearce, B. D. (2001). Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms. Mol. Psychiatry 6, 634–646. doi: 10.1038/sj.mp.4000956
Perry, V. H. (2007). Stress primes microglia to the presence of systemic inflammation: implications for environmental influences on the brain. Brain Behav. Immun. 21, 45–46. doi: 10.1016/j.bbi.2006.08.004
Potter, E. D., Ling, Z. D., and Carvey, P. M. (1999). Cytokine-induced conversion of mesencephalic-derived progenitor cells into dopamine neurons. Cell Tissue Res. 296, 235–246. doi: 10.1007/s004410051285
Potvin, S., Stip, E., Sepehry, A. A., Gendron, A., Bah, R., and Kouassi, E. (2008). Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 63, 801–808. doi: 10.1016/j.biopsych.2007.09.024
Rouse, B. T., and Sehrawat, S. (2010). Immunity and immunopathology to viruses: what decides the outcome? Nat. Rev. Immunol. 10, 514–526. doi: 10.1038/nri2802
Rutherford, B. R., Pott, E., Tandler, J. M., Wall, M. M., Roose, S. P., and Lieberman, J. A. (2014). Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry 71, 1409–1421. doi: 10.1001/jamapsychiatry.2014.1319
Sathyasaikumar, K. V., Stachowski, E. K., Wonodi, I., Roberts, R. C., Rassoulpour, A., McMahon, R. P., et al. (2011). Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr. Bull. 37, 1147–1156. doi: 10.1093/schbul/sbq112
Schwarcz, R., Rassoulpour, A., Wu, H. Q., Medoff, D., Tamminga, C. A., and Roberts, R. C. (2001). Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50, 521–530. doi: 10.1016/S0006-3223(01)01078-2
Sommer, I. E., de Witte, L., Begemann, M., and Kahn, R. S. (2012). Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J. Clin. Psychiatry 73, 414–419. doi: 10.4088/JCP.10r06823
Sommer, I. E., van Westrhenen, R., Begemann, M. J., de Witte, L. D., Leucht, S., and Kahn, R. S. (2014). Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr. Bull. 40, 181–191. doi: 10.1093/schbul/sbt139
Sørensen, H. J., Mortensen, E. L., Reinisch, J. M., and Mednick, S. A. (2009). Association between prenatal exposure to bacterial infection and risk of schizophrenia. Schizophr. Bull. 35, 631–637. doi: 10.1093/schbul/sbn121
Sparkman, N. L., and Johnson, R. W. (2008). Neuroinflammation associated with aging sensitizes the brain to the effects of infection or stress. Neuroimmunomodulation 15, 323–330. doi: 10.1159/000156474
Sperner-Unterweger, B., Barnas, C., Fuchs, D., Kemmler, G., Wachter, H., Hinterhuber, H., et al. (1992). Neopterin production in acute schizophrenic patients: an indicator of alterations of cell-mediated immunity. Psychiatry Res. 42, 121–128. doi: 10.1016/0165-1781(92)90076-F
Steen, R. G., Mull, C., McClure, R., Hamer, R. M., and Lieberman, J. A. (2006). Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br. J. Psychiatry 188, 510–518. doi: 10.1192/bjp.188.6.510
Steiner, J., Walter, M., Glanz, W., Sarnyai, Z., Bernstein, H. G., Vielhaber, S., et al. (2013). Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 70, 271–278. doi: 10.1001/2013.jamapsychiatry.86
Stone, T. W. (1993). Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 45, 309–379.
Takano, A., Arakawa, R., Ito, H., Tateno, A., Takahashi, H., Matsumoto, R., et al. (2010). Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int. J. Neuropsychopharmacol. 13, 943–950. doi: 10.1017/S1461145710000313
Teixeira, A. L. Jr., Maia, D. P., and Cardoso, F. (2007). Psychosis following acute Sydenham's chorea. Eur. Child Adolesc. Psychiatry 16, 67–69. doi: 10.1007/s00787-006-0566-z
van Berckel, B. N., Bossong, M. G., Boellaard, R., Kloet, R., Schuitemaker, A., Caspers, E., et al. (2008). Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry 64, 820–822. doi: 10.1016/j.biopsych.2008.04.025
van Dam, A. P. (1991). Diagnosis and pathogenesis of CNS lupus. Rheumatol. Int. 11, 1–11. doi: 10.1007/BF00290244
Versijpt, J. J., Dumont, F., van Laere, K. J., Decoo, D., Santens, P., Audenaert, K., et al. (2003). Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur. Neurol. 50, 39–47. doi: 10.1159/000070857
Vincent, A., and Bien, C. G. (2008). Anti-NMDA-receptor encephalitis: a cause of psychiatric, seizure, and movement disorders in young adults. Lancet Neurol. 7, 1074–1075. doi: 10.1016/S1474-4422(08)70225-4
Westergaard, T., Mortensen, P. B., Pedersen, C. B., Wohlfahrt, J., and Melbye, M. (1999). Exposure to prenatal and childhood infections and the risk of schizophrenia: suggestions from a study of sibship characteristics and influenza prevalence. Arch. Gen. Psychiatry 56, 993–998. doi: 10.1001/archpsyc.56.11.993
Wildenauer, D. B., Körschenhausen, D., Hoechtlen, W., Ackenheil, M., Kehl, M., and Lottspeich, F. (1991). Analysis of cerebrospinal fluid from patients with psychiatric and neurological disorders by two-dimensional electrophoresis: identification of disease-associated polypeptides as fibrin fragments. Electrophoresis 12, 487–492. doi: 10.1002/elps.1150120706
Winter, C., Djodari-Irani, A., Sohr, R., Morgenstern, R., Feldon, J., Juckel, G., et al. (2009). Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. Int. J. Neuropsychopharmacol. 12, 513–524. doi: 10.1017/S1461145708009206
Yolken, R. H., and Torrey, E. F. (1995). Viruses, schizophrenia, and bipolar disorder. Clin. Microbiol. Rev. 8, 131–145.
Zhou, D., Kusnecov, A. W., Shurin, M. R., DePaoli, M., and Rabin, B. S. (1993). Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology 133, 2523–2530.
Keywords: inflammation, schizophrenia, psychoneuroimmunology, neuroinflammation, COX-2
Citation: Müller N, Weidinger E, Leitner B and Schwarz MJ (2015) The role of inflammation in schizophrenia. Front. Neurosci. 9:372. doi: 10.3389/fnins.2015.00372
Received: 09 March 2015; Accepted: 28 September 2015;
Published: 21 October 2015.
Edited by:
Luca Steardo, Sapienza University of Rome, ItalyTommaso Cassano, University of Foggia, Italy
Reviewed by:
Susan Powell, University of California at San Diego, USAMarcello Solinas, Institut National de la Santé et la Recherche Medicale, France
Copyright © 2015 Müller, Weidinger, Leitner and Schwarz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Norbert Müller, Tm9yYmVydC5NdWVsbGVyQG1lZC51bmktbXVlbmNoZW4uZGU=